ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

about

Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology.The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases.

P2860

Q47153925-F0A21025-83BB-4565-8716-1722794E76D0 Q47604110-C1BD159F-EE7F-440D-B8F5-E1BFF7274013

P2860

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

Item

http://www.wikidata.org/entity/Q38626147

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

@en

type

Item

label

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

@en

prefLabel

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

@en

P1476

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients

@en

P2093

Paul Hofman

http://www.w3.org/2001/XMLSchema#string

P2860

Crizotinib resistance: implications for therapeutic strategies

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.

Detection of gene rearrangements in targeted clinical next-generation sequencing.

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.

Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization

P31

scholarly article

P356

10.3390/CANCERS9080106

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul Hofman

P577

2017-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28805673

http://www.w3.org/2001/XMLSchema#string

P932

5575609

http://www.w3.org/2001/XMLSchema#string

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

about

P2860

P2860

ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P932